Payment overview · 2025
General Payments
$439,373.90
624 reported records · 19 companies
Healthcare provider profile · identity verified
Idan Sharon, M.D.
Allopathic & Osteopathic Physicians|General Practice · BROOKLYN, NY · NPI 1205852845
Verified facts
What the public records show
CMS Open Payments records show Idan Sharon, M.D. received $439,373.90 in general payments during 2025 across 624 reported records.
ABBVIE INC. accounted for 14.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aplenzin, Austedo Xr, Auvelity, Caplyta, Fanapt, Lybalvi, Nurtec Odt, Qulipta, Rexulti, Trintellix, Ubrelvy, Valtoco, Vraylar, Xcopri, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 247 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Lybalvi by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Auvelity by this doctor in 2024.
Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APLENZIN as an associated drug or biological on 9096 records involving 3309 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Aplenzin by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Caplyta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 360 claims for Rexulti by this doctor in 2024.
Neurelis, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VALTOCO as an associated drug or biological on 16082 records involving 5567 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Valtoco by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 360 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Nurtec Odt by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ztlido by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Xcopri by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Trintellix by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Austedo Xr by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65,064.36 | 14.8% | 72 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59,016.75 | 13.4% | 80 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $55,752.57 | 12.7% | 66 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $53,336.28 | 12.1% | 59 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50,944.97 | 11.6% | 66 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $47,954.10 | 10.9% | 89 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $42,846.53 | 9.8% | 52 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $35,983.60 | 8.2% | 42 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$13,061.47 | 3.0% | 18 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $8,444.58 | 1.9% | 17 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$5,908.59 | 1.3% | 11 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $312.48 | 0.1% | 16 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $238.93 | 0.1% | 9 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $177.29 | 0.0% | 10 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $172.98 | 0.0% | 9 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $55.18 | 0.0% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $43.07 | 0.0% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.37 | 0.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $27.80 | 0.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $323,667.00 | 135 |
| Honoraria | $62,175.00 | 27 |
| Travel and Lodging | $23,223.85 | 125 |
| Food and Beverage | $21,399.00 | 329 |
| Consulting Fee | $8,818.75 | 6 |
| Education | $90.30 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $59,016.75 | 80 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $53,336.28 | 59 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $51,183.90 | 75 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $47,954.10 | 89 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $42,763.03 | 51 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $35,983.60 | 42 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $31,780.38 | 35 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31,676.11 | 31 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $23,972.19 | 31 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17,166.11 | 21 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16,318.93 | 25 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $13,014.88 | 16 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $8,428.69 | 14 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $5,908.59 | 11 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $312.48 | 16 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $177.29 | 10 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $172.98 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $152.46 | 9 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $55.18 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $43.07 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $32.37 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $27.80 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| APLENZIN aplenzin |
2025 | Aplenzin | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 81 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Auvelity auvelity |
2025 | Auvelity | 2024 | 105 | exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 98 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 143 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 95 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 360 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 184 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 169 | exact normalized | Medicare Part D |
| VALTOCO valtoco |
2025 | Valtoco | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 247 | exact normalized | Medicare Part D |
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 281 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
95 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
169 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
247 | 36 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
98 | 14 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
105 | 17 |
| Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | APLENZIN open payments reported associated product |
CMS Open Payments — General Payments 9096 supporting records · 3309 recipient NPIs · example record 1239973605 |
Aplenzin · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
360 | 72 |
| Neurelis, Inc. Exact reporting entity; no affiliate inference |
2025 | VALTOCO open payments reported associated product |
CMS Open Payments — General Payments 16082 supporting records · 5567 recipient NPIs · example record 1219183925 |
Valtoco · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
360 | 72 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
143 | 21 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
281 | 30 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
184 | 32 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Escitalopram Oxalate | Escitalopram Oxalate | 446 | 87 |
| Rexulti | Brexpiprazole | 360 | 72 |
| Clonazepam | Clonazepam | 284 | 66 |
| Xcopri | Cenobamate | 281 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 268 | 36 |
| Bupropion Xl | Bupropion Hcl | 261 | 56 |
| Vraylar | Cariprazine Hcl | 247 | 36 |
| Paroxetine Hcl | Paroxetine Hcl | 230 | 49 |
| Trintellix | Vortioxetine Hydrobromide | 184 | 32 |
| Gabapentin | Gabapentin | 180 | 30 |
| Adlarity | Donepezil Hcl | 173 | 24 |
| Alprazolam | Alprazolam | 171 | 42 |
| Ubrelvy | Ubrogepant | 169 | 29 |
| Nurtec Odt | Rimegepant Sulfate | 143 | 21 |
| Lorazepam | Lorazepam | 131 | 30 |
| Celecoxib | Celecoxib | 128 | 48 |
| Sertraline Hcl | Sertraline Hcl | 115 | 23 |
| Memantine Hcl | Memantine Hcl | 113 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 19 |
| Aimovig Autoinjector | Erenumab-Aooe | 105 | 13 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 105 | 17 |
| Lybalvi | Olanzapine/Samidorphan Malate | 98 | 14 |
| Qulipta | Atogepant | 95 | 13 |
| Risperidone | Risperidone | 95 | 12 |
| Aripiprazole | Aripiprazole | 83 | 15 |
| Donepezil Hcl | Donepezil Hcl | 83 | 25 |
| Austedo Xr | Deutetrabenazine | 81 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 80 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 13 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 73 | suppressed |
| Diazepam | Diazepam | 70 | 13 |
| Lurasidone Hcl | Lurasidone Hcl | 69 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 17 |
| Quviviq | Daridorexant Hcl | 58 | 13 |
| Gralise | Gabapentin | 57 | 13 |
| Lamotrigine | Lamotrigine | 57 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 56 | 12 |
| Mirtazapine | Mirtazapine | 55 | 16 |
| Lamotrigine Er | Lamotrigine | 54 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 53 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 12 |
| Trazodone Hcl | Trazodone Hcl | 53 | 15 |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Rivastigmine | Rivastigmine | 49 | 14 |
| Olanzapine | Olanzapine | 47 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 45 | suppressed |
| Ztlido | Lidocaine | 41 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Caplyta | Lumateperone Tosylate | 38 | suppressed |
| Fycompa | Perampanel | 37 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 35 | suppressed |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Loreev Xr | Lorazepam | 35 | suppressed |
| Aplenzin | Bupropion Hbr | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Ingrezza | Valbenazine Tosylate | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | 11 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Lacosamide | Lacosamide | 28 | suppressed |
| Austedo | Deutetrabenazine | 27 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 25 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Valtoco | Diazepam | 25 | suppressed |
| Horizant | Gabapentin Enacarbil | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 21 | suppressed |
| Neupro | Rotigotine | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 18 | suppressed |
| Adzenys Xr-Odt | Amphetamine | 17 | suppressed |
| Fanapt | Iloperidone | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Vimpat | Lacosamide | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Onzetra Xsail | Sumatriptan Succinate | 13 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 12 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $439,373.90 · 624 records | ABBVIE INC. | APLENZIN, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, FANAPT, LYBALVI, Leqembi, NURTEC ODT, QULIPTA, Qelbree, REXULTI, SPRAVATO, Symbravo, TRINTELLIX, UBRELVY, VALTOCO, VRAYLAR, XCOPRI, ZAVZPRET, ZENPEP, ZTLido | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aplenzin play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error